Increased IgA responses to the LPS of commensal bacteria is associated with inflammation and activation of cell-mediated immunity in chronic fatigue syndrome. — CFSMEATLAS
Increased IgA responses to the LPS of commensal bacteria is associated with inflammation and activation of cell-mediated immunity in chronic fatigue syndrome.
Maes, Michael, Twisk, Frank N M, Kubera, Marta et al. · Journal of affective disorders · 2012 · DOI
Quick Summary
This study found that people with ME/CFS have higher levels of immune antibodies (IgA) that react to bacteria normally living in their gut. These elevated antibodies were connected to increased inflammation and immune system activation in the blood. The more of these antibodies patients had, the worse their symptoms—including fatigue, brain fog, and digestive problems—tended to be.
Why It Matters
This research provides a mechanistic link between gut bacteria, immune dysfunction, and symptom severity in ME/CFS, suggesting that bacterial translocation and resulting immune responses may drive disease activity in a subset of patients. Understanding this pathway could lead to targeted diagnostic biomarkers and therapeutic interventions addressing intestinal barrier dysfunction.
Observed Findings
Serum IL-1, TNFα, neopterin, and elastase were significantly higher in ME/CFS patients compared to chronic fatigue patients.
Positive correlations existed between IgA responses to LPS and all inflammatory markers (IL-1, TNFα, neopterin, elastase).
Patients with abnormally high IgA responses showed increased serum cytokine levels and higher IBS symptom ratings.
Inflammatory markers (IL-1, TNFα, neopterin) correlated with fatigue severity, neurological symptoms, and mood disturbances.
Inferred Conclusions
Increased IgA responses to commensal bacterial LPS are associated with systemic inflammation and cell-mediated immune activation in ME/CFS.
Bacterial translocation or increased intestinal permeability may contribute to disease activity through immune activation in some ME/CFS patients.
Inflammatory pathways linked to bacterial recognition are associated with the full spectrum of ME/CFS symptoms, not just fatigue.
Remaining Questions
Does bacterial translocation precede symptom onset, or does it develop secondary to ME/CFS pathology?
Which specific mechanisms lead to increased intestinal permeability and bacterial translocation in affected patients?
Could interventions targeting intestinal barrier integrity or modulating IgA responses improve outcomes in ME/CFS patients with elevated bacterial antibodies?
What This Study Does Not Prove
This study does not prove that bacterial translocation causes ME/CFS, only that it is associated with the disease in some patients. The cross-sectional design cannot establish whether immune activation triggers bacterial translocation or results from it. Additionally, elevated antibodies alone do not demonstrate active bacterial translocation—they indicate immune recognition of bacterial components.